FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3139687514> ?p ?o ?g. }

• W3139687514 endingPage "899" @default.
• W3139687514 startingPage "889" @default.
• W3139687514 abstract "Background Effects of human umbilical cord blood (HUCB) as a valuable source for stem cell-based therapies have not been studied in persistent post-5-alpha reductase inhibitors (5ARI) erectile dysfunction (PPED). Aim To determine the effect of intracavernosal injection of HUCB mononuclear cells (MNCs) on ED associated with dutasteride treatment. Methods Twenty five adult male Sprague-Dawley rats were divided into 5 groups (n = 5 per group): (i) control, (ii) 8-week dutasteride (0.5 mg/kg/day, in drinking water), (iii) 12-week dutasteride, (iv) 8-week dutasteride+HUCB-MNCs (1 × 106) and (v) 12-week dutasteride+HUCB-MNCs. HUCB-MNCs were administered intracavernosally after eight weeks of dutasteride treatment. Experiments were performed at 4 weeks following the injection of HUCB-MNCs. Erectile responses and isometric tension of corpus cavernosum (CC) were measured. The protein expressions of phosphodiesterase type 5 (PDE5), endothelial nitric oxide synthase (eNOS), neuronal NOS (nNOS), hypoxia-inducible factor (HIF)-1α and smooth muscle/collagen contents in penile tissue were evaluated by Western blotting, immunohistochemistry, and Masson's trichrome staining, respectively. Main Outcome In vivo erectile function, in vitro relaxant and contractile responses of CC, protein expression and localization of PDE5, eNOS, nNOS, HIF-1α, and smooth muscle content in penile tissue. Results Erectile responses in the dutasteride-treated groups were significantly decreased compared with controls (P < .001), persisting after 4-wk of washout. HUCB-MNCs restored diminished intracavernosal pressure responses, acetylcholine-, sodium nitroprusside-, sildenafil-induced relaxations, and increased phenylephrine and electrical field stimulation (EFS)-induced contractions. Decreased EFS-induced relaxations in dutasteride-treated groups were not restored by HUCB-MNCs. Increased PDE5 and reduced nNOS expressions in dutasteride groups were restored by HUCB-MNCs in the 12-week dutasteride group. eNOS and HIF-1α protein expression and serum total and free testosterone levels were similar among groups. HUCB-MNCs reversed the decreased smooth muscle/collagen ratio in dutasteride-treated tissues. There was a significant increase in PDE5 and HIF-1α staining in 8-week dutasteride animals. Clinical Translation This study demonstrates the corrective potential of HUCB-MNCs on some persistent structural and functional deterioration caused by 5ARI treatment in rats, which may encourage further evaluation of HUCB-MNCs in men with PPED. Strengths and Limitations Therapeutic application of intracavernosal HUCB-MNCs is a novel approach for the rat model of post-5ARI ED. Lack of serum and tissue dihydrotestosterone measurements, vehicle injections and characterization of the cells remain limitations of our study. Conclusion The persistent ED after prolonged administration of dutasteride in rats is reversed by HUCB-MNC treatment, which holds promise as a realistic therapeutic modality for this type of ED. Oztekin CV, Yilmaz-Oral D, Kaya-Sezginer E, et al. Beneficial Effects of Human Umbilical Cord Blood Mononuclear Cells on Persistent Erectile Dysfunction After Treatment of 5-Alpha Reductase Inhibitor in Rats. J Sex Med 2021;18:889–899." @default.
• W3139687514 created "2021-04-13" @default.
• W3139687514 creator A5003979928 @default.
• W3139687514 creator A5013759531 @default.
• W3139687514 creator A5018543356 @default.
• W3139687514 creator A5040358062 @default.
• W3139687514 creator A5041577160 @default.
• W3139687514 creator A5043791264 @default.
• W3139687514 creator A5072348280 @default.
• W3139687514 creator A5075278753 @default.
• W3139687514 date "2021-05-01" @default.
• W3139687514 modified "2023-10-15" @default.
• W3139687514 title "Beneficial Effects of Human Umbilical Cord Blood Mononuclear Cells on Persistent Erectile Dysfunction After Treatment of 5-Alpha Reductase Inhibitor in Rats" @default.
• W3139687514 cites W1511884192 @default.
• W3139687514 cites W1542310964 @default.
• W3139687514 cites W1558621919 @default.
• W3139687514 cites W1935088196 @default.
• W3139687514 cites W1968790411 @default.
• W3139687514 cites W1969281312 @default.
• W3139687514 cites W1985892943 @default.
• W3139687514 cites W1986147205 @default.
• W3139687514 cites W1993110783 @default.
• W3139687514 cites W1994586809 @default.
• W3139687514 cites W2039211272 @default.
• W3139687514 cites W2040239032 @default.
• W3139687514 cites W2040319341 @default.
• W3139687514 cites W2063521742 @default.
• W3139687514 cites W2063836318 @default.
• W3139687514 cites W2064070589 @default.
• W3139687514 cites W2064757601 @default.
• W3139687514 cites W2107337149 @default.
• W3139687514 cites W2110887669 @default.
• W3139687514 cites W2117234036 @default.
• W3139687514 cites W2119921883 @default.
• W3139687514 cites W2125818234 @default.
• W3139687514 cites W2142623609 @default.
• W3139687514 cites W2148846485 @default.
• W3139687514 cites W2149932590 @default.
• W3139687514 cites W2151709067 @default.
• W3139687514 cites W2151743953 @default.
• W3139687514 cites W2173839721 @default.
• W3139687514 cites W2309525264 @default.
• W3139687514 cites W2494949166 @default.
• W3139687514 cites W2496999162 @default.
• W3139687514 cites W2521933461 @default.
• W3139687514 cites W2568015330 @default.
• W3139687514 cites W2593339698 @default.
• W3139687514 cites W2607763466 @default.
• W3139687514 cites W2805117509 @default.
• W3139687514 cites W2809240273 @default.
• W3139687514 cites W2888795018 @default.
• W3139687514 cites W2902320442 @default.
• W3139687514 cites W2908460454 @default.
• W3139687514 cites W2919569756 @default.
• W3139687514 cites W2942281766 @default.
• W3139687514 cites W2951862441 @default.
• W3139687514 cites W2954491818 @default.
• W3139687514 cites W2971086259 @default.
• W3139687514 cites W2972687981 @default.
• W3139687514 cites W3012104684 @default.
• W3139687514 cites W4235388995 @default.
• W3139687514 cites W4254329016 @default.
• W3139687514 cites W2767431929 @default.
• W3139687514 doi "https://doi.org/10.1016/j.jsxm.2021.02.005" @default.
• W3139687514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33785264" @default.
• W3139687514 hasPublicationYear "2021" @default.
• W3139687514 type Work @default.
• W3139687514 sameAs 3139687514 @default.
• W3139687514 citedByCount "3" @default.
• W3139687514 countsByYear W31396875142022 @default.
• W3139687514 countsByYear W31396875142023 @default.
• W3139687514 crossrefType "journal-article" @default.
• W3139687514 hasAuthorship W3139687514A5003979928 @default.
• W3139687514 hasAuthorship W3139687514A5013759531 @default.
• W3139687514 hasAuthorship W3139687514A5018543356 @default.
• W3139687514 hasAuthorship W3139687514A5040358062 @default.
• W3139687514 hasAuthorship W3139687514A5041577160 @default.
• W3139687514 hasAuthorship W3139687514A5043791264 @default.
• W3139687514 hasAuthorship W3139687514A5072348280 @default.
• W3139687514 hasAuthorship W3139687514A5075278753 @default.
• W3139687514 hasConcept C126322002 @default.
• W3139687514 hasConcept C134018914 @default.
• W3139687514 hasConcept C163031210 @default.
• W3139687514 hasConcept C203014093 @default.
• W3139687514 hasConcept C2776955114 @default.
• W3139687514 hasConcept C2777622882 @default.
• W3139687514 hasConcept C2778326061 @default.
• W3139687514 hasConcept C2779610285 @default.
• W3139687514 hasConcept C2779698670 @default.
• W3139687514 hasConcept C2779929075 @default.
• W3139687514 hasConcept C2780559512 @default.
• W3139687514 hasConcept C519581460 @default.
• W3139687514 hasConcept C71924100 @default.
• W3139687514 hasConcept C74534348 @default.
• W3139687514 hasConcept C98274493 @default.
• W3139687514 hasConceptScore W3139687514C126322002 @default.
• W3139687514 hasConceptScore W3139687514C134018914 @default.
• W3139687514 hasConceptScore W3139687514C163031210 @default.

• next